Sham Mailankody, MBBS

Sham Mailankody is a medical oncologist and hematologist at Memorial Sloan Kettering Cancer Center specializing in the care of people with multiple myeloma and related plasma cell disorders. He completed his MBBS from K.S. Hegde Medical Academy followed by residencies in internal medicine from Georgetown University/Washington Hospital Center and fellowships in medical oncology from National Cancer Institute. Dr Mailankody is board certified in medical oncology and internal medicine.

With his colleagues at Memorial Sloan Kettering Cancer Center, Sham Mailankody is focused on identifying optimal treatment strategies for people with these disorders and is interested in the molecular pathways underlying progression of plasma cell disorders and the development of targeted strategies aiming to delay, prevent, and cure full-blown disease. He also has an interest in health policy as it relates to oncologic drug approvals and the cost of cancer care.

Representative Publications:

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

Dietary intake is associated with risk of multiple myeloma and its precursor disease

Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma

Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma